Sinphar Pharmaceutical Co. Ltd. · TWSE:1734
Sinphar Pharmaceutical — 2021 Sinphar Pharmaceutical Investor Conference
26 slides from Sinphar Pharmaceutical's conference presentation, Nov 11, 2021
Slide 1: Sinphar Pharmaceutical Investor Conference
1734 TT 4192 TT SINPHAR PHARMACEUTICAL CO.,LTD Investor Conference Chairman 李志文 GM 白友烺 & CFO 陳至孝 11 November 2021 1
Slide 2: Disclaimer
免責聲明 ◼ 本簡報是建立於本公司從各項來源所取得之資 訊。有些資訊可能受未來不確定性因素影響， 致使與原先本公司對於未來前景的說明迥異。 未來若有變更或調整時，請以公開資訊觀測站 公告資訊為依據。 ◼ This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cau
Slide 3: Index
Index 1. Instruction 2. Group Operation 3. 2021Q3 Financial Report 4. Important Events 5. Social Responsibility 3
Slide 4: Founded in Taiwan, Step Forward to The World
Founded in Taiwan, Step Forward to The World 1977 2002 2012 Established Sinphar Invested Sinphar TianLi, He-Tian Tianli Merged ZuniMed Biotech Ilan, Taiwan Hangzhou (CN)、Xinjiang(CN) Nantou,TW Generic、functional food、 Generic、TCM、Natural Resources Medical facilities cosmetic 1997 2008 Established Ca
Slide 5: Group's Great Health Map
Group’s Great Health Map Multi-strength of Generic Drugs The R&D power of New Drug Strategic plan of Natural Herbal Resources 5
Slide 6: Full age and all-round protection
Full age and all-round protection Vision care Brain care Heart care Dermatology Ophthalmology Pediatrics Immune Gastrointestinal Oncology Otolaryngology Orthopedics Bone health care regulation care Allergy Obstetrics & Beauty care Delay aging General Surgery Plastic Surgery regulation Gynecology Chr
Slide 7: Sinphar Health Counters
Sinphar Health Counters Share relevant medical and health knowledge with the public ： 1.Strengthen direct services with members. (By 2021, about 46,000 people will join the membership) 2. Strengthen customer service- related after-sales medical and health care knowledge 7 3. Online sales channels
Slide 8: Sinphar Health Park
Sinphar Health Park 1. Since the opening of the park, 760 delegations have visited (about 7,300 people in 2021) to understand the manufacturing process and rigorous spirit of pharmaceuticals, food and maintenance products, and nearly 20,000 people are expected to visit the factory in 2022. 2. A free
Slide 9: Intelligent manufacturing plant SAP MES
Intelligent manufacturing plant ISO/IEC 27001 ◼ Inspection 進貨 IQC 入庫 SAP SAP 領料 ◼ Automatic sorting 秤料 粉碎 MES WMS S ◼ Auto-filter A 過篩 P 混料 ◼ Automatic ◼ Auto-packing ◼ Insspection ◼ Electronic manufacturing label 充填 合格 合格 檢驗 分裝 貼標 包裝 檢驗 入庫 不合格 不合格 空膠囊 剔除 剔除 ASPROVA
Slide 10: Sustainable Management
Sustainable Management Energy Carbon Saving Reducing Average annual power savings 47 % reduction in direct of greenhouse gas emissions 3% Reduced sludge removal by approx. 18 % 10
Slide 11: Growth
Growth Therapeutic drug • New listings are expected in 2022：4。 • Co-develop and manufacture with Japanese pharmaceutical companies and attack the ASEAN market. • API in-depth development plan. Functional Supplements • New listings are expected in 2022 ：3。 • Agent Japanese products into the domestic
Slide 12: Export
Export Japan： Mongolia ： Product G，Launched in 2020. Product L，Launched in 2020. Thailand ： Product E，Launched in 2023. Product T，Launched in 2022. Indonesia ： Product A，Launched in 2024. Product A，Launched in 2020. Malaysia ： Product B，Launched in 2022Q1. Product T，Launched in 2020. Vietnam ： Produ
Slide 13: Group resources integration
Group resources integration Sinphar & SynCore Drugs in R & D cooperation and manufacturing improve. Sinphar & TianLi Oncology R&D achievement mutually Dosages benefit. Patents cooperation layout. Natural Medical Herbal Facilities Resources Sinphar & ZuniMed ISO15378 Class 100,000 clean room. 13
Slide 14: Sinphar Group's New Drug Catalog
For more information, please Sinphar Group's New Drug Catalog refer to the annual reports. SB05 PC Memoregain Pancreatic cancer SB03 Veregen® Vascular dementia Second-line therapy：Clinical phase Ⅲ data is Genital warts Drug Permit License under investigation Listed in 20 countries First-line therap
Slide 15: Pipeline of New Products
Pipeline of New Products 專注未滿足的醫療/市場需求 Focus on Unmet Medical Needs Oncology Dermatology Ophthalmology Ocular Diagnostic 15
Slide 16: Development of New Drug
Development of New Drug Market value From Market Research Engine, the global market value of Pancreatic Cancer will increase to US$13 billion in 2021. According to GLOBOCAN,Pancreatic cancer mortality rate is almost equal to incidence, which is expected to increase by 40% by 2030. Market Research En
Slide 17: R&D achievement
R&D achievement 2021 America’s Science & Invention Expo 2021 XV International Warsaw Invention Show TianLife SCI papers. patents granted in countries. year Achievement 2020 • 3 patents were obtained. • 4 patents were obtained. • With the goal of becoming a world-class food 2021 ingredient and sellin
Slide 18: Target field of Natural Resources
Target field of Natural Resources Lipucan® Protygold ® Memoregain® TLCT Plus 天力速康® 杏补宜 ® 天力再生® (Poria cocos triterpenoids) (Walnut oligopeptide) (Cistanche tubulosa extracts) Sleep quality Sports Nutrition Boost Respiratory Health Proven by healthy study (3 multinational patents) (4 multinational pa
Slide 19: Recent group revenue
Recent group revenue NTD in Thousand 2,000,000 1,800,000 1,600,000 1,400,000 療效用藥 1,200,000 1,000,000 功能性食品 800,000 其他 600,000 400,000 合計 200,000 0 2018Q1-Q3 2019Q1-Q3 2020Q1-Q3 2021Q1-Q3 Term 2018年Q1-Q3 2019年Q1-Q3 2020年Q1-Q3 2021年Q1-Q3 2020 Therapeutic 1,112,925 1,180,870 1,243,483 1,157,494 1,585,
Slide 20: Profit and Loss
Profit and Loss NTD in Thousand Sinphar gruop 2021Q1~Q3 2020Q1~Q3 Revenue 1,792,176 1,847,962 Gross Profit 36% 38% S&M -250,076 -239,222 G&A -149,418 -160,773 R&D -418,416 -344,107 Net income (loss) -161,845 -83,336 Net income (loss) attributable to parent -23,099 25,547 company’s shareholders Synco
Slide 21: Cash flows
Cash flows NTD in Thousand Sinphar Gruop Syncore 2021Q3 2021Q3 Net Cash generated by 55,074 -174,379 operating activities Net Cash used in investing -123,350 -975 activities Net Cash generated by 138,222 268,625 financing activities Cash and cash equivalents, 1,209,365 632,449 end of the period NTD
Slide 22: Ratio
Ratio 2021Q3 2020Q3 Debt ratio(%) 49.65 49.24 Current ratiob(%) 180.30 187.73 Account receivable turnover 4.96 4.31 Account payable turnover 7.42 7.00 Inventory turnover 2.16 2.45 The increase in inventory was mainly due to the advance stocking in response to the epidemic. 22
Slide 23: 2021 events
2021 events 1. Lipucan® after obtaining 55 patents from 16 countries, the research results were published on the previous day 「Life 2021, 11(2), 111」and 「Life 2021, 11(5), 372 」. Empirical extraction of valuable (Lanostanes) ingredients from the earthen cyst can enhance the body's first line of defe
Slide 24: Corporate Social Responsibility
贊助Oxaliplatin予國家衛生研究院 執行胰臟癌IIT試驗，以促進國內對於胰臟癌治療之研究 Corporate Social Responsibility Promote social care, medical prevention and health education 1. Host health forum, biotechnology camp. Combined medical, academia, and biotechnology community to set up an interaction platform. Also, cultivate talented
Slide 25: Corporate Social Responsibility
贊助Oxaliplatin予國家衛生研究院 執行胰臟癌IIT試驗，以促進國內對於胰臟癌治療之研究 Corporate Social Responsibility Support sports and educational activities in long term 1. Sponsor kaohsiung Medical University for a total of 5 million yuan over 5 years, attract talented people and help disadvantaged students to attend school at ease
Slide 26: Q&A
Q&A • 合作與開發： 張智超。 (02-27603688 # 2304) • 投資人服務： 樓怡美。 (02-27603688 # 2216) 26
Sinphar Pharmaceutical — 2021 Sinphar Pharmaceutical Investor Conference on 6ix